Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically ...

Reports Q2 revenue $5,000 vs $5,000 last year. “Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive ...